The methodology for developing modified release granules based on phytoextracts for the treatment of mastopathy
DOI:
https://doi.org/10.24959/nphj.24.156Keywords:
mastopathy; granules with modified release; methodology; phytoextractsAbstract
Aim. To substantiate the scientific and methodological approach to the development of the composition and technology of granules based on phytoextracts with modified release of active substances for the complex treatment of mastopathy.
Materials and methods. The research was conducted by processing electronic and paper sources of information on the etiopathogenetic factors of mastopathy, the concept of developing medicinal products with modified release of active pharmaceutical ingredients (APIs), the market analysis of medicines and dietary supplements (DS) for the treatment of mastopathy.
Results. An information search has been conducted to study the etiology, pathogenesis, clinical manifestations and pharmacotherapy of breast diseases. The article presents and substantiates the stages of experimental research on the development of a medicinal product in the form of granules based on phytoextracts with a modified release of active substances, including marketing and statistical research methods of electronic and paper sources of information on the prevalence and consequences of mastopathy, development of granules based on phytoextracts with a modified release of APIs, standardization, preclinical studies of the medicinal product developed.
Conclusions. The scientific and methodical approach to the development of the composition and technology of granules based on phytoextracts with a modified API release for the complex pharmacocorrection of mastopathy and prevention of the appearance of malignant neoplasms in breast tissues has been substantiated.
References
Malherbe, K., Khan, M., Fatima, S. (2023). Fibrocystic Breast Disease. Florida: StatPearls Publishing. Available at: https://pubmed.ncbi.nlm.nih.gov/31869073.
Danino, M. A., El Khatib, A. M., Doucet, O., Dao, L., Efanov, J. I., Bou-Merhi, J. S. et al. (2019). Preliminary Results Supporting the Bacterial Hypothesis in Red Breast Syndrome following Postmastectomy Acellular Dermal Matrix- and Implant-Based Reconstructions. Plastic and Reconstructive Surgery, 144(6), 988e-992e. doi: 10.1097/PRS.0000000000006227.
Orr, B., Kelley, J. L. (2016). 3rd. Benign breast diseases: evaluation and management. Clin Obstet Gynecol., 59(4), 710-726. doi: 10.1097/GRF.0000000000000233.
Stachs, A., Stubert, J., Reimer, T., Hartmann, S. (2019). Benign breast disease in women. Deutsches Arzteblatt international., 116(33-34), 565-574. doi: 10.3238/arztebl.2019.0565.
Eberl, M. M., Phillips, R.L. Jr., Lamberts, H., Okkes, I., Mahoney, M. C. (2008). Characterizing breast symptoms in family practice. Annals of Family Medicine., 6(6), 528-533. doi: 10.1370/afm.905.
Dyrstad, S. W., Yan, Y., Fowler, A. M., Colditz, G. A. (2015). Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Research and Treatment, 149(3), 569-575. DOI: 10.1007/s10549-014-3254-6.
Bulletin of the National Cancer Registry of Ukraine. (2024 (25)). Morbidity, mortality, performance indicators of the oncology service. Onco-epidemiological situation and the state of the organization of oncology care in Ukraine, 2022-2023. Kyiv.
Compendium 2019 - medicinal products (2019) / Ed. V. N. Kovalenko. Kyiv: MORION.
Phuong, H. L., Tran, Thao, T. D. Tran (2020). Dosage form designs for the controlled drug release of solid dispersions. International Journal of Pharmaceutics, 581, 119274. doi: 10.1016/j.ijpharm.2020.119274.
Marín, V., Burgos, V., Pérez, R., Durvanei, A. M., Pardi, P., Paz, C. (2023). The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment. International Journal of Molecular Sciences., 24(13), 10737. doi: 10.3390/ijms241310737.
Lopes, C. M., Dourado, A., Oliveira, R. (2017). Phytotherapy and Nutritional Supplements on Breast Cancer. BioMed Research International, 2017, 7207983. doi: 10.1155/2017/7207983.
MOZ Ukrainy. State Register of Medicinal Products of Ukraine. Available at: http://www.drlz.kiev.ua.
Al-Hashimi, N., Begg, N., Alany, R. G., Hassanin, H., Elshaer, A. (2018). Oral Modified Release Multiple-Unit Particulate Systems: Compressed Pellets, Microparticles and Nanoparticles. Pharmaceutics, 10(4), 176. doi: 10.3390/pharmaceutics10040176.
Yerkhova, A., Katynska, M. (2021). Characteristics and justification of the use of pellets as a modern dosage form on the market of Ukraine. Ukrainian Scientific and Medical Youth Journal, 4(127), 92-98.
State pharmacopoeia of Ukraine (2015). State enterprise «Ukrainian Scientific Pharmacopoeia Center for the Quality of Medicinal Products». Kharkiv: Derzhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv».
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
